Infectoflam (cinnarizine + gentamicin): Uses, Dosage & Side Effects

What it's for (Indications)

It is crucial to note that a fixed-dose combination product specifically combining cinnarizine and gentamicin is not a widely recognized or standard pharmaceutical entity in most major markets.
Therefore, specific primary indications for such a combined 'medicine' are not established.
However, based on the pharmacological properties of its individual components, if such a product were hypothetically formulated, its use might be considered in very specific and complex scenarios.
Cinnarizine is typically prescribed for symptomatic relief of vertigo, dizziness, tinnitus, nausea, and vomiting associated with Meniere's disease or other vestibular disorders.
Gentamicin, on the other hand, is a potent broad-spectrum aminoglycoside antibiotic primarily used for treating severe bacterial infections, but it is also utilized in an intratympanic formulation for chemical labyrinthectomy in refractory Meniere's disease to ablate vestibular function.
The co-formulation would present significant therapeutic challenges due to the divergent risk-benefit profiles and routes of administration typically associated with these two agents.
Therefore, without a defined and approved formulation, indications remain speculative and would require robust clinical evidence.

Dosage Information

Type	Guideline
Standard	As a fixed-dose combination of cinnarizine and gentamicin is not a standard, approved pharmaceutical product, there are no established, evidence-based dosing guidelines. The appropriate dosage for each component would typically vary significantly based on the intended therapeutic effect, route of administration, patient's renal function, age, weight, and the severity of the condition being treated. For example, oral cinnarizine dosage for vertigo typically ranges from 25 mg to 75 mg taken orally two to three times daily. In contrast, gentamicin dosage for systemic bacterial infections is usually calculated based on body weight (e.g., 3-5 mg/kg/day, often divided into multiple doses or as a single daily dose, adjusted for renal function), and administered intravenously or intramuscularly. Intratympanic gentamicin for Meniere's disease involves direct instillation into the middle ear, with varying protocols regarding concentration and frequency. Combining these into a single 'medicine' would necessitate precise formulation and extensive pharmacokinetic/pharmacodynamic studies to determine safe and effective dosing, which are currently unavailable for this speculative product.

Type

Guideline

Standard

As a fixed-dose combination of cinnarizine and gentamicin is not a standard, approved pharmaceutical product, there are no established, evidence-based dosing guidelines. The appropriate dosage for each component would typically vary significantly based on the intended therapeutic effect, route of administration, patient's renal function, age, weight, and the severity of the condition being treated. For example, oral cinnarizine dosage for vertigo typically ranges from 25 mg to 75 mg taken orally two to three times daily. In contrast, gentamicin dosage for systemic bacterial infections is usually calculated based on body weight (e.g., 3-5 mg/kg/day, often divided into multiple doses or as a single daily dose, adjusted for renal function), and administered intravenously or intramuscularly. Intratympanic gentamicin for Meniere's disease involves direct instillation into the middle ear, with varying protocols regarding concentration and frequency. Combining these into a single 'medicine' would necessitate precise formulation and extensive pharmacokinetic/pharmacodynamic studies to determine safe and effective dosing, which are currently unavailable for this speculative product.

Safety & Warnings

Common Side Effects

The spectrum of potential side effects for this hypothetical combination would encompass those associated with both cinnarizine and gentamicin, with the severe risks of gentamicin being paramount.
**Cinnarizine** commonly causes central nervous system effects such as drowsiness, sedation, and fatigue.
Other reported side effects include gastrointestinal disturbances like nausea, dyspepsia, and dry mouth.
Less frequently, allergic skin reactions, headache, and weight gain can occur.
In elderly patients, cinnarizine has been associated with extrapyramidal symptoms, including Parkinsonism, especially with prolonged use.
**Gentamicin** carries a high risk of serious adverse effects, including **nephrotoxicity** (renal impairment, acute kidney injury) and irreversible **ototoxicity** (vestibular dysfunction leading to vertigo, ataxia, nystagmus, and auditory loss including tinnitus and deafness).
The risk of these severe effects is dose-dependent, duration-dependent, and increased with pre-existing renal impairment, dehydration, or co-administration of other nephrotoxic or ototoxic drugs.
Other gentamicin-related side effects include neuromuscular blockade (leading to muscle weakness, respiratory depression), hypersensitivity reactions, electrolyte disturbances (e.
g.
, hypomagnesemia, hypocalcemia), and peripheral neuropathy.
The combination would necessitate extremely careful patient selection and rigorous monitoring to mitigate these profound risks.

Serious Warnings

Black Box Warning: Gentamicin, a key component of this hypothetical combination product, carries a significant Black Box Warning concerning **nephrotoxicity** and **ototoxicity**. Renal impairment, manifested by elevated serum creatinine and BUN, oliguria, and proteinuria, is a common and serious adverse effect, particularly with prolonged treatment, high doses, or in patients with pre-existing renal dysfunction. The risk of nephrotoxicity is higher in dehydrated patients and the elderly. Furthermore, irreversible **ototoxicity**, affecting both vestibular and auditory function, can occur. Vestibular symptoms include vertigo, ataxia, and dizziness, while auditory symptoms may include hearing loss and tinnitus. These effects can be permanent and are more likely in patients with pre-existing hearing loss, renal impairment, or when given concurrently with other ototoxic drugs. Careful monitoring of renal function and auditory/vestibular function is imperative during therapy. Neuromuscular blockade and respiratory paralysis have also been reported, especially after rapid intravenous administration or in patients with neuromuscular disorders. The benefit-risk profile must be thoroughly assessed before initiating treatment with any product containing gentamicin.
As this is a hypothetical combination of cinnarizine and gentamicin, several critical warnings would apply, primarily driven by the severe adverse effect profile of gentamicin.
Patients should be explicitly warned about the high potential for irreversible **ototoxicity** (hearing loss and vestibular damage) and significant **nephrotoxicity** (kidney damage).
Renal function must be meticulously assessed before initiating therapy and monitored throughout treatment, especially in elderly patients, those with impaired renal function, or those receiving concomitant nephrotoxic drugs.
Auditory and vestibular function should also be monitored regularly.
The product should be used with extreme caution in patients with neuromuscular disorders, such as Myasthenia Gravis, due to the risk of exacerbating muscle weakness and potentially inducing respiratory paralysis.
Patients should be advised about the central nervous system depressant effects of cinnarizine, including drowsiness and sedation, and cautioned against driving or operating heavy machinery.
Concomitant use with alcohol or other CNS depressants should be avoided.
The potential for drug interactions, particularly with other ototoxic, nephrotoxic, or neuromuscular blocking agents, requires thorough evaluation before administration.
Pregnant or breastfeeding individuals should generally avoid this product due to fetal/infant risks.

How it Works (Mechanism of Action)

The 'medicine' cinnarizine + gentamicin would exert its effects through the distinct pharmacological mechanisms of its two components. **Cinnarizine** primarily functions as an antihistamine (H1 receptor antagonist) with calcium channel blocking properties. It acts directly on the vestibular system, inhibiting the stimulation of the labyrinthine sensory cells, which helps to reduce vertigo, nausea, and nystagmus. By blocking calcium influx into vestibular hair cells, it decreases their excitability, thereby alleviating symptoms associated with vestibular disorders. Additionally, it has vasodilatory effects by blocking calcium channels in vascular smooth muscle, improving microcirculatory blood flow, though its primary anti-vertigo effect is localized. **Gentamicin** is an aminoglycoside antibiotic that exerts its bactericidal action by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding interferes with bacterial protein synthesis, leading to the production of abnormal or non-functional proteins, ultimately resulting in bacterial cell death. Beyond its antibiotic properties, gentamicin is also known for its **vestibulotoxic effects**, particularly when administered directly into the inner ear (intratympanically), where it selectively damages vestibular hair cells, leading to a chemical labyrinthectomy. This vestibulotoxic action is mediated by uptake into hair cells, leading to oxidative stress and apoptosis, a mechanism exploited in treating intractable Meniere's disease.